Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BA1105
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BA1105 is a recombinant anti-Claudin18.2 human IgG1 monoclonal antibody for treating Claudin18.2-positive advanced solid tumors. BA1105 alone or in combination with chemotherapeutic agents demonstrated a strong anticancer activity in tumor models.
Brand Name : BA1105
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 05, 2021
Lead Product(s) : BA1105
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?